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Synopsis: 
Core Wash Cytology can be used as an adjunct to regular Core Needle Biopsy of breast lesions to provide a 
reliable provisional cytological diagnosis within one hour of biopsy, and is highly conclusive in malignant 
lesions. 
 
Abstract: 
Background: Fine Needle Aspiration Biopsy (FNAB), Core Needle biopsy (CNB) and hybrid techniques 
including Core Wash Cytology (CWC) are available for same-day diagnosis in breast lesions. In CWC a washing 
of the biopsy core is processed for a provisional cytological diagnosis, after which the core is processed like a 
regular CNB. This study focuses on the reliability of CWC in daily practice.  
Methods: All consecutive CWC procedures performed in a referral breast centre between May 2009 and May 
2012 were reviewed, correlating CWC results with the CNB result, definitive diagnosis after surgical resection 
and/or follow-up. Symptomatic as well as screen-detected lesions, undergoing CNB were included. 
Results: 1,253 CWC procedures were performed. Definitive histology showed 849 (68%) malignant and 404 
(32%) benign lesions. 80% of CWC procedures yielded a conclusive diagnosis: this percentage was higher 
amongst malignant lesions and lower for benign lesions: 89% and 62% respectively. Sensitivity and specificity 
of a conclusive CWC result were respectively 98.3% and 90.4%. The eventual incidence of malignancy in the 
cytological ‘atypical’ group (5%) was similar to the cytological ‘benign’ group (6%).  
Conclusion: CWC can be used to make a reliable provisional diagnosis of breast lesions within the hour. The 
high probability of conclusive results in malignant lesions makes CWC well suited for high risk populations. 
 
Keywords: breast neoplasms, diagnosis, biopsy, cytological techniques  
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Introduction: 
In the United states, 222 175 women were diagnosed with breast cancer in 2011[1]. Although National 
Comprehensive Cancer Network (NCCN) guidelines make no mention of the preferred duration of diagnostic 
workup[2], European guidelines encourage rapid confirmation or exclusion of cancer within 24-48 hours[3]. 
Especially patients with benign disease benefit from reduced duration of anxiety[4], in malignant cases a quick 
confirmation expedites subsequent treatment. To meet this challenge, different approaches have been developed.  
 
Fine Needle Aspiration Biopsy (FNAB) allows a diagnosis within an hour, with sensitivity of 35-95%, 
specificity of 48-100% and conclusivity of 60-75%[5]. This has progressively led most clinics to adopt Core 
Needle Biopsy (CNB) as diagnostic tool of choice.[5-9]. Considered as the gold standard for evaluating solid 
breast lesions[5-9], CNB often requires more processing time. Recently, the accelerated CNB processing method 
has demonstrated a reliable histological diagnosis on the day of biopsy[10].  However, alternative techniques are 
also available.  
 
In an attempt to combine speed and accuracy a hybrid technique, Core Wash Cytology (CWC) of a CNB 
specimen (CNB+CWC), combining cytology and histology, was developed. The CNB specimen and needle are 
‘washed’ in a saline solution or special fixative which is then cytocentrifugated and pressed onto a slide. The 
resulting cytology specimen is interpreted using the same guidelines as used for FNAB[11]. Afterwards the Core 
itself provides a histological diagnosis. After an initial promising study [12], a second larger series [13] found 
the technique performed poorly, with a low specificity (72%) and an unacceptably high inconclusive rate (42%).  
 
Following a successful pre-clinical pilot study[14], our breast clinic adopted a modified CWC technique for the 
evaluation of solid breast lesions. A review of this technique describing 229 patients showed excellent results 
with a sensitivity of 97%, a specificity of 100% and an inconclusive rate of 4%[15]. To our knowledge, no series 
validating or evaluating CWC in breast cancer have been published since. 
 
The aim of the present study was to relate the previous pilot results to a larger consecutive daily practice series 
of patients diagnosed using standardized CNB+CWC in a regional breast clinic over a 3 year period. 
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Materials:  
Patient selection, database 
The prospectively filled National Pathology Database of the Netherlands (PALGA[16]) was searched to identify 
all CNB procedures of the breast in our clinic, between May 1, 2009 and May 31, 2012, including both 
symptomatic and screen detected lesions. All patients with CWC following CNB were included. We analysed 
baseline patient characteristics including age, referral indication and ‘Breast imaging- reporting and data system’ 
(BI-RADS)[17] classification. CWC- and CNB result, as well as information on hormone receptor- and HER2 
status were recorded. Furthermore, we included post-operative pathology results and neo-adjuvant therapy in our 
database.  
 
Biopsies 
CNB was performed using US-, stereotactic- or MRI guidance. US-guided biopsies were performed using an 18 
gauge needle on a BARD® magnum® biopsy gun. The number of cores for each biopsy was at the discretion of 
the radiologist. Stereotactic and MRI guided biopsies were performed with a Vacuum Assisted Biopsy (VAB) 
system. VAB specimens were not processed using the CWC procedure, and were excluded from this study.  
 
CWC technique 
Technical details of the modified CWC procedure have been described in previous reports[14, 15]. In short: after 
biopsy the CNB specimen is placed in a transport solution (initially Roswell Park Memorial Institute (RPMI), 
later replaced with a 50% ethanol/2% polyethylene glycol solution). After removing the CNB specimen for 
regular processing, cells remaining in the medium are cyto-centrifugated, processed to a monolayer slide and 
stained according to Papanicolaou.  
  
Pathology 
The CWC specimen is interpreted within one hour following biopsy, using the same criteria as for FNAB. 
According to international guidelines[11], findings are categorized as ‘insufficient material’ (inconclusive), 
‘benign’, ‘atypical favouring benign’, ‘atypical’ (inconclusive), ‘suspicious for malignancy’ or ‘malignant’. CNB 
specimens were processed and reported on according to the Dutch national breast cancer guidelines[18]. The 
report includes both a classification (‘benign’, ‘not clearly benign/suspected malignancy’ or ‘malignant’) and a 
specific diagnosis. The specimen were formalin-fixed, embedded in paraffin and at least three cuts were taken. 
For our database, we recorded the CNB result as benign, high risk (including lobular carcinoma in situ, atypical 
ductal/lobular hyperplasia and complex sclerosing lesion), DCIS or invasive cancer.  
Post-operative pathology specimens were also processed and reported according to the Dutch national 
guidelines. All specimens were evaluated by experienced breast pathologists. 
 
Follow-up 
For patients with a benign biopsy result whose lesions were not resected, we performed a nationwide search in 
the ‘PALGA’[16] database in July 2013, checking for breast related malignancy diagnosed after the biopsy 
procedure to identify potential false negative results.  
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Data-analysis 
We considered benign and “atypical favouring benign” results as ‘benign’, insufficient material and inconclusive 
(atypical) as ‘inconclusive’, suspicious and malignant as ‘malignant’.  
For descriptive purposes, we used the type of benign lesion found at CNB to describe benign lesions of patients 
not operated on.  
For calculation of sensitivity and specificity of the CWC result, the most ‘definitive’ diagnosis available was 
used: post-operative pathology if available, otherwise CNB results combined with follow-up through PALGA. 
Data was analysed using SPSS (IBM® SPSS® statistics version 19) (SPSS Inc., Chicago, IL, USA). Statistical 
significance was tested using the chi-square test, with a cut off value of 0.05. 
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Results:  
Patients 
During the studied period 1 516 patients underwent 1 820 CNB procedures for the evaluation of 1 768 breast 
lesions. Of these 1 253 (69%) were processed using the CWC procedure, the remaining 567 specimen were 
acquired using (stereotactic) VAB and thus not suitable for a ‘one-stop-shop’ CWC approach. General 
radiologists performed 53 biopsies (4.2%), dedicated breast radiologists performed 1 200 (95.8%) biopsies. 
Patient and lesion characteristics are shown in table 1. Of these lesions 35% were screen detected. 
 
Of the patients analysed with the CWC procedure, 70 (5.6%) subsequently received neo-adjuvant systemic 
therapy, leading to a pathologic complete response in 6 patients (8.6%). For our analysis we considered the 
‘definitive’ diagnosis in these patients to be malignant. 
Final diagnosis through surgical excision was available for 894 lesions, of which 776 (87%) were malignant.  
 
CWC results 
Of the 1 253 CWC procedures 1 007 (80%) provided a conclusive result. We classified 240 as ‘benign’ and 767 
as ‘malignant’ (table 2). We classified 246 specimens (20%) as ‘inconclusive’. Of these, a conclusive CNB 
diagnosis was reached the next day in 197 (80%) cases; in 49 cases (20%) CNB remained inconclusive.  
The definitive diagnosis of ‘inconclusive’ CWC specimen was benign in 157 cases (64%) and malignant in 89 
cases (36%, p < 0.001). Of all lesions benign on final histology, 38% were inconclusive on CWC. Of the 
malignant lesions, 11% were inconclusive on CWC. 
Malignant lesions with a Bloom-Richardson classification (BR grade) 1 were more often inconclusive on CWC 
than those with a BR grade 3 (15% versus 5%, p=0.005). CWC of invasive lobular carcinoma was more often 
inconclusive than that of invasive ductal carcinoma (22% versus 7%, p < 0.001).  
 
CNB results 
In 91 cases (7%) the CNB specimen did not reveal a definitive diagnosis. In 74 (81%) cases because of doubt on 
representativity of the biopsy, in 8 (9%) cases because of insufficient material and in 9 (10%) biopsies the 
diagnosis was formally inconclusive. In 41 of these cases repeat CNB was performed and  in 29 cases a surgical 
excision biopsy. For 21 patients radiographic and/or clinical follow-up was preferred.  
In 49 (54%) of cases with an inconclusive CNB, CWC was inconclusive as well. For 36 cases (39%) CWC 
correctly predicted outcome, for 6 cases (7%) CWC did not correctly predict the final result. 
 
In 31 cases, CWC and CNB showed contradictory results. In 25 of these, CWC indicated malignancy whereas 
the final CNB result showed a benign lesion. A repeated CNB and/or resection was performed in 19 cases, 
revealing malignancy in 9 cases. 
In 6 cases CWC indicated a benign lesion and CNB a malignancy. In 5 of these cases a repeat biopsy and/or 
resection was performed, revealing malignant disease in all 5 cases. 
 
The PALGA search  was performed for the 355 patients with a conclusive benign CNB result. Median available 
follow-up was 30 months, with a range of 12-49 months. Eight patients were subsequently diagnosed with breast 
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cancer. Three cases concerned contralateral breast lesions. The remaining five were considered false negatives 
(only one of these five was conclusive at initial CWC). 
 
The percentage of ‘conclusive’ CWC results was 80%. Sensitivity of a conclusive CWC result was 98.3%, 
specificity 90.4%. Of the ‘conclusive’ CWC results, 38 were incorrect (3.8%). 
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Discussion:  
This series is the largest available in the current literature on Core Wash Cytology in breast lesions. It  provides 
clear test characteristics and guidance on interpretation of atypical, inconclusive, and suspicious results. Unlike 
our previous series[15] it includes many benign cases, making it more representative of daily clinical practice. 
The very high sensitivity of a conclusive result makes CWC particularly suitable for immediate reassurance of 
patients with benign disease.  
The hybrid nature of the procedure means each biopsy functions as its own internal control. The resection 
specimen and follow up through the Dutch national pathology database PALGA provide a strong external 
control, making it unlikely that false positive and/or false negative results were missed. The equipment and 
experience required for this technique are the same as for FNA-acquired breast cytology. 
 
As CWC is an additional rather than an alternative processing procedure, extra information is created. Most 
often, this information is confirmed by other sources. However, in approximately 3% of cases CNB and CWC 
results are contradictory. As expected, a malignant CNB result is reliable when CWC indicates benign disease. 
Conversely, when CNB was benign but CWC indicated malignancy about one third of cases proved malignant 
after resection. Thus, CWC provides a (modest) reduction in false negative CNB results. One explanation could 
be the presence of a very small fragment of malignant tissue in the biopsy core, completely disintegrating during 
transport to the pathology department. Malignant cells would then be found on CWC, though no malignant 
lesion is found in CNB. 
 
Using a liquid based cytology method and processing the CWC specimen to a monolayer slide takes slightly 
more time (approximately 20 minutes) and effort, compared to performing a ‘direct smear’ technique. We 
believe this to be worthwhile, as previous literature shows interpretation time is reduced, cellular morphology is 
improved, and there are less inconclusive results[19, 20].  
 
The most important limitation of CWC is the number of inconclusive results. In the previous series[15] in line 
with FNAB guidelines[11] we considered ‘atypical favouring benign’ to be inconclusive. This series clearly 
demonstrate an atypical result can be considered conclusively benign (table 4). This is  remarkable, as FNAB 
series show a prevalence of malignancy in this category of about 37%[21-23]. The proportion of atypical results 
in the present series (6.4%) is somewhat higher than large FNAB series (3.9 and 4%)[21, 23] possibly indicating 
our pathologists reporting more atypical lesions other pathologists might have reported as benign (inter-observer 
variation). Furthermore, there could be a difference in population (mostly symptomatic in the present series), or 
an intrinsic difference between CWC and FNAB specimen. 
 
When considering atypical results as conclusively benign, 20% of CWC procedures was inconclusive. This was 
higher (38%) for benign lesions. Conversely, only 11% was inconclusive in malignant lesions. This is in line 
with literature concerning FNAB, and the previous series by Uematso[13, 24]. CWC performs favourably 
compared to FNAB series showing 27-42% inconclusiveness[19].  
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A correlation between differentiation grade and conclusivity was observed: in BR grade 3 lesions only 5% was 
inconclusive whereas BR grade 1 lesions are, in terms of conclusivity (15%), in between high grade 
malignancies and benign lesions. 
More inconclusive results among lobular carcinomas mirrors previous literature[25]. Cells of invasive lobular 
carcinoma may be hard to distinguish from lymphocytes in cytology specimen. 
 
The CWC procedure allows us to run a true ‘one-stop-shop’ breast clinic. It provides 80% of patients, suitable 
for ultrasound guided biopsy, a diagnosis within hours of entering our clinic. In daily practice, patients 
sequentially visit the radiology department and the outpatient clinic, and immediately receive a preliminary 
diagnosis based on cytology, combined with history, physical examination and imaging. This strategy results in 
95% of patients receiving a tentative conclusion and corresponding treatment plan or reassurance the same day. 
It also facilitates the immediate planning of treatment and/or further analysis when required. The combination 
with regular CNB processing means we can provide 99% of patients with a conclusive diagnosis the following 
day, without the necessity of repeat biopsy. This policy limits the duration of anxiety, cost and the number of 
invasive procedures. Furthermore it helps to streamline treatment planning, reducing time and number of office 
visits between initial diagnosis and additional diagnostics or treatment. Although the relatively small decrease in 
time will not likely result in a survival benefit[26], in our experience it is greatly appreciated by patients.  
 Of all patients expecting a diagnosis within an hour of biopsy, we have to disappoint approximately 5%. 
Managing expectations is therefore crucial to patient-satisfaction.  
 
This series paints a more realistic picture of CWC compared to our first clinical series. Differences can be 
explained by a more balanced case mix with more benign lesions in the present series. Comparison to our first 
series and the study by Uematso et all. points out the crucial fact that CWC is well suited for high-risk 
populations, but less so for low risk groups [13, 15]. With increasing numbers of benign lesions test 
characteristics and specifically conclusivity show a marked drop. The Uematso series contains less than 50% 
malignant cases, and has an inconclusive rate of over 40%. However, when conclusivity for malignant- and 
benign lesions is taken separately results are more similar to ours. 
Interestingly, Lankford et al. provide very different results with excellent test characteristics and an inconclusive 
rate of only 7% even though their population was extremely low risk with only 13% malignant lesions[12]. Their 
population is different, as it only included non-palpable lesions. Furthermore a different, 4 point classification 
for CWC results was used rather than the internationally accepted criteria for FNAB cytology[11]. Another 
explanation could be that the increased conclusivity reported by Lankford comes at the cost of decreased 
sensitivity (82% versus 98% for a conclusive result in the present series). 
 
Compared to FNAB or regular CNB, the CWC technique has clear advantages. CWC is much faster than regular 
CNB, whilst retaining the advantages through the additionally processed core. Unlike FNAB, the CNB specimen 
serves as an internal quality assurance, greatly reducing the number of repeat biopsies that accompanies an 
inconclusive FNAB result[24]. Processing in under one hour is superior to the 4-6 hours required for accelerated 
CNB, and the technique is far less logistically demanding[10].  
 
10 
 
We excluded stereotactic biopsies, because a much larger gauge needle is generally used, decreasing the surface 
to volume-ratio of the specimen. Moreover, stereotactic biopsies are often scheduled one to several days after 
initial evaluation of mostly screen-detected lesions, and these patients have a lower prevalence of malignancy 
and more DCIS. For these reasons we do not perform CWC for stereotactic biopsies. 
 
Although this study was retrospective, we were able to reliably retrieve all relevant variables. Our study reflects 
real-life daily practice, including many benign cases, less experienced radiologists and samples of lesser quality. 
These unpolished results can be considered representative for the high volume breast clinic. 
 
Conclusion: 
In the largest series currently available, we demonstrated that Core Wash Cytology can be used as an adjunct to 
regular Core Needle Biopsy to make a provisional diagnosis on breast lesions within one hour of biopsy. The 
technique has a good specificity and a very high sensitivity provided the diagnosis is conclusive. However, 20% 
inconclusive results means the technique is not well suited for populations with a high prevalence of benign 
breast disease.  
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Table 1. Patient characteristics  
Total: 
 female 
 male 
1 253 
1 244 (99.3%) 
9 (0.7%) 
Age in years (median, range) 55 (16-96) 
Referral indication: 
 palpable breast lesion 
 screening  
 incidental radiologic finding 
 breast pain 
 follow up after malignancy 
 other 
 
544 (43.4%) 
435 (34.7%) 
76 (6.1%) 
41 (3.3%) 
54 (4.3%) 
100 (8.2%) 
BI-RADSa classification: 
 0 
 1 
 2 
 3 
 4 
 5 
 Unknown 
 
1 (0.1%) 
1 (0.1%) 
18 (1.4%) 
240 (19.2%) 
392 (31.3%) 
547 (43.6%) 
54 (4.3%) 
Patients previously evaluated for 
breast complaintsb 
501 (40%) 
Patients previously diagnosed with 
breast cancer 
128 (10.2%) 
a BI-RADS: Breast imaging – reporting and data system 
b Not including the National breast cancer screening program 
 
Table 2. Distribution of Core Wash Cytology diagnosis 
Final classification: 
 0: not enough material 
 1: benign 
 2: atypia 
 3: inconclusive 
 4: suspicious 
 5: malignant 
 
104 (8.3%) 
160 (12.8%) 
80 (6.4%) 
142 (11.3%) 
97 (7.7%) 
670 (53.5%) 
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Table 3. Lesion characteristics 
Nature of lesiona: 
 Benign 
o Fibroadenoma 
o (micro) cystic 
o Fibrotic tissue 
o Other 
 high riskb 
 DCISc 
 invasive carcinoma 
o ductal 
o lobular 
o other 
 
395 (31.5%) 
 144 (36.5%) 
 5 (1.3%) 
 58 (14.7%) 
 188 (47.6%) 
9 (0.7%) 
33 (2.6%) 
816 (65.1%) 
 647 (79.9%) 
 100 (12.3%) 
 61 (7.4%) 
Nature of invasive lesiona 
 Bloom-richardson 
classification 
o Grade 1 
o Grade 2 
o Grade 3 
o Unknown 
 Estrogen receptor status 
o Positive 
o Negative 
o Unknown 
 Progesterone receptor 
status 
o Positive 
o Negative 
o Unknown 
 HER2 status 
o Positive 
o Negative 
o Unknown 
Total: 816 (100%) 
 
 
161 (19.7%) 
344 (42.2%) 
198 (24.3%) 
113 (13.8%) 
 
677 (83%) 
111 (13.6%) 
28 (3.4%) 
 
 
522 (64% 
266 (32.6%) 
28 (3.4%) 
 
71 (8.7%) 
564 (69.1%) 
181 (22.2%) 
a most definitive result: resection when available, otherwise CNB result 
b e.g. atypical ductal hyperplasia, lobular carcinoma in situ 
c Ductal Carcinoma in Situ 
 
Table 4: Core Wash Cytology result versus most definitive result availableab 
 Final Histologyab 
CWCc  Benign High risk DCISd Invasive cancer 
1: benign 149 1 3 7 
2: atypia 74 2 0 4 
3: inconclusive 152 2 6 86 
4: suspicious 9 1 5 82 
5: malignant 11 3 19 637 
a most definitive result: resection when available, otherwise CNB result 
b Italics signify false positive- or false negative results 
c Core Wash Cytology 
d Ductal Carcinoma in Situ 
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Figure 1: Core Wash Cytology. Resulting macroscopy of a Core Wash slide (A). Resulting microscopy of a Core 
Wash slide. Malignant epithelial cells with large nucleoli. Pap staining, magnification 400x (B).  
 
